Sort   by:  
 Page size 
UnknownPrediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters.
Not available
S-EPMC4559831 | biostudies-literature
UnknownPOLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
Not available
S-EPMC4627582 | biostudies-literature
Unknownp53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
Not available
S-EPMC7613653 | biostudies-literature
UnknownClinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
Not available
S-EPMC5834053 | biostudies-literature
UnknownPrognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Not available
S-EPMC10050005 | biostudies-literature
UnknownAdjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
Not available
S-EPMC12479390 | biostudies-literature
UnknownAdjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Not available
S-EPMC6722042 | biostudies-literature
UnknownAdjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Not available
S-EPMC5840256 | biostudies-literature
Sort   by:  
 Page size